

Appl. No. : 09/619,059
Filed : July 18, 2000

14. (Amended) The composition according to claim 2, wherein said nerve growth factor has a concentration of 0.1 to about 2.0 mg/ml and said acetate-containing buffer comprises an acetate ion having a concentration of 10 mM to 50 mM.

Sub 157
15. (Amended) The composition of claim 2, wherein the NGF concentration is 0.1 mg/ml, the acetate-containing buffer is 20 mM sodium acetate, and wherein the composition further comprises a sodium chloride concentration of 136 mM, a benzyl alcohol concentration of 0.9% (v/v), and wherein the composition is about pH 5.5.

B3
16. (Amended) The composition of claim 2, wherein the NGF concentration is 2.0 mg/ml, the acetate-containing buffer is 10 mM sodium acetate, and wherein the composition further comprises a sodium chloride concentration of 142 mM, and wherein the composition is about pH 5.5.

B4 Sub 157
21. (Amended) The composition of claim 18, wherein the nerve growth factor is secreted and purified from Chinese hamster ovary cells.

REMARKS

In response to the Office Action mailed October 01, 2001, Applicants respectfully request the Examiner to reconsider the above-captioned application in view of the foregoing amendments and the following comments. Claims 2-21 are pending and stand rejected. Claims 2, 10, 13, 14, 15, 16, and 21 have been amended. No new matter has been added and support for these amendments is provided in the original claims and throughout the specification. Entry of these amendments and reconsideration of this application is respectfully requested.

The specific changes to the specification and the amended claims are shown on a separate set of pages attached hereto and entitled VERSION WITH MARKINGS TO SHOW CHANGES MADE, which follows the signature page of this Amendment. On this set of pages, the insertions are underlined while the ~~deletions are stricken through~~.

Double patenting

The Examiner has rejected claims 2-21 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over the claims of U.S. Patent No. 6,090,781. Applicants have submitted a terminal disclaimer with this Amendment addressing U.S. Patent No. 6,090,781.